William Sharfman

5PUBLICATIONS
53CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Apr 21, 2026
MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.

|Jan 31, 2025
Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study.

Shailender Bhatia, Suzanne L Topalian, William Sharfman

|Jan 22, 2024
Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers.

Kara M Schenk, Julie Stein Deutsch, Sunandana Chandra

|Oct 15, 2021
An Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma.

Merve Hasanov, Denái R Milton, William H Sharfman

|Sep 30, 2015
Interleukin-2, Ipilimumab, and Anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanoma.

Tasha Hughes, Matthew Klairmont, William H Sharfman

Pageof 1

Frequent Collaborators

2 joint publications

Suzanne L Topalian

1 joint publications

Merve Hasanov

1 joint publications

Bret Taback

1 joint publications

Lee D Cranmer